Results: 1-18 |
Results: 18

Authors: Ko, YJ Small, EJ Kabbinavar, F Chachoua, A Taneja, S Reese, D DePaoli, A Hannah, A Balk, SP Bubley, GJ
Citation: Yj. Ko et al., A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer, CLIN CANC R, 7(4), 2001, pp. 800-805

Authors: Taplin, ME Bubley, GJ Rajeshkumar, B Shuster, T Ko, YJ Morganstern, DE
Citation: Me. Taplin et al., Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer, SEMIN ONCOL, 28(4), 2001, pp. 32-39

Authors: Bubley, GJ
Citation: Gj. Bubley, Is the flare phenomenon clinically significant?, UROLOGY, 58(2A), 2001, pp. 5-9

Authors: Fair, WR Trachtenberg, J Bubley, GJ Heston, WD Peehl, DM Newling, DWW
Citation: Wr. Fair et al., Discussion following Dr. William R. Fair's presentation of Dr. Paul F. Schellhammer's paper, UROLOGY, 58(2A), 2001, pp. 15-15

Authors: Fair, WR Stricker, HJ Lieberman, R Bubley, GJ Trachtenberg, J Heston, WDW
Citation: Wr. Fair et al., Discussion following Dr. Hans J. Stricker's presentations, UROLOGY, 58(2A), 2001, pp. 27-27

Authors: Daniell, HW Chen, S Fair, WR Heston, WDW Pirani, JF Bubley, GJ Carroll, PR Gleave, ME
Citation: Hw. Daniell et al., Discussion following Dr. Sophie Chen's (pages 28-35) and Dr. John F. Pirani's presentations, UROLOGY, 58(2A), 2001, pp. 38-38

Authors: Lieberman, R Gleave, ME Carroll, PR Bubley, GJ
Citation: R. Lieberman et al., Discussion following Dr. Martin E. Gleave's presentation, UROLOGY, 58(2A), 2001, pp. 48-49

Authors: Trachtenberg, J Grossfeld, GD Lubeck, DP Bubley, GJ Carroll, PR Fair, WR Newling, DWW
Citation: J. Trachtenberg et al., Discussion following Dr. Gary D. Grossfeld's presentation, UROLOGY, 58(2A), 2001, pp. 64-64

Authors: Carroll, PR D'Amico, A Malkowicz, SB Gleave, ME Bubley, GJ
Citation: Pr. Carroll et al., Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer - Discussion, UROLOGY, 58(2A), 2001, pp. 82-82

Authors: Stanbrough, M Leav, I Kwan, PWL Bubley, GJ Balk, SP
Citation: M. Stanbrough et al., Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium, P NAS US, 98(19), 2001, pp. 10823-10828

Authors: Jones, GB Hynd, G Wright, JM Purohit, A Plourde, GW Huber, RS Mathews, JE Li, AW Kilgore, MW Bubley, GJ Yancisin, M Brown, MA
Citation: Gb. Jones et al., Target-directed enediynes: Designed estramycins, J ORG CHEM, 66(11), 2001, pp. 3688-3695

Authors: Ali Tahir, SM Cheng, O Shaulov, A Koezuka, Y Bubley, GJ Wilson, SB Balk, SP Exley, MA
Citation: Sm. Ali Tahir et al., Loss of IFN-gamma production by invariant NK T cells in advanced cancer, J IMMUNOL, 167(7), 2001, pp. 4046-4050

Authors: Eder, JP Kantoff, PW Roper, K Xu, GX Bubley, GJ Boyden, J Gritz, L Mazzara, G Oh, WK Arlen, P Tsang, KY Panicali, D Schlom, J Kufe, DW
Citation: Jp. Eder et al., A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer, CLIN CANC R, 6(5), 2000, pp. 1632-1638

Authors: Jones, GB Mitchell, MO Weinberg, JS D'Amico, AV Bubley, GJ
Citation: Gb. Jones et al., Towards enzyme activated antiprostatic agents, BIOORG MED, 10(17), 2000, pp. 1987-1989

Authors: Bubley, GJ Carducci, M Dahut, W Dawson, N Daliani, D Eisenberger, M Figg, WD Freidlin, B Halabi, S Hudes, G Hussain, M Kaplan, R Myers, C Oh, W Petrylak, DP Reed, E Roth, B Sartor, O Scher, H Simons, J Sinibaldi, V Small, EJ Smith, MR Trump, DL Vollmer, R Wilding, G
Citation: Gj. Bubley et al., Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group, J CL ONCOL, 17(11), 1999, pp. 3461-3467

Authors: Taplin, ME Bubley, GJ Ko, YJ Small, EJ Upton, M Rajeshkumar, B Balk, SP
Citation: Me. Taplin et al., Selection for androgen receptor mutations in prostate cancers treated withandrogen antagonist, CANCER RES, 59(11), 1999, pp. 2511-2515

Authors: Cenni, B Kim, HK Bubley, GJ Aebi, S Fink, D Teicher, BA Howell, S Christen, RD
Citation: B. Cenni et al., Loss of DNA mismatch repair facilitates reactivation of a reporter plasmiddamaged by cisplatin, BR J CANC, 80(5-6), 1999, pp. 699-704

Authors: Chott, A Sun, Z Morganstern, D Pan, J Li, T Susani, M Mosberger, I Upton, MP Bubley, GJ Balk, SP
Citation: A. Chott et al., Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor, AM J PATH, 155(4), 1999, pp. 1271-1279
Risultati: 1-18 |